Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.

Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment / Pepin, M.; Ferreira, A. C.; Arici, M.; Bachman, M.; Barbieri, M.; Bumblyte, I. A.; Carriazo, S.; Delgado, P.; Garneata, L.; Giannakou, K.; Godefroy, O.; Grodzicki, T.; Klimkowicz-Mrowiec, A.; Kurganaite, J.; Liabeuf, S.; Mocanu, C. A.; Paolisso, G.; Spasovski, G.; Vazelov, E. S.; Viggiano, D.; Zoccali, C.; Massy, Z. A.; Wiecek, A.; Capasso, G.; Andrade, A.; Bachmann, M.; Bumblyte, I.; Covic, A. C.; Delgado, P.; Endlich, N.; Engvig, A.; Fouque, D.; Franssen, C.; Frische, S.; Garneata, L.; Gesualdo, L.; Giannakou, K.; Goumenos, D.; Kartal, A. T.; Mani, L. -Y.; Marti, H. -P.; Mayer, C.; Nielsen, R.; Psic, V.; Rroji, M.; Sakkas, G.; Spasovski, G.; Stevens, K. I.; Vazelov, E.; Viggiano, D.; Zacharia, L.; Ferreira, A. C.; Malyszko, J.; Hoorn, E.; Figurek, A.; Unwin, R.; Wagner, C. A.; Wanner, C.; Bruchfeld, A.; Pepin, M.; Nitsch, D.; Fridolin, I.; Hafez, G.; Soler, M. J.; Batinic, B.; Carrasco, L.; Carriazo, S.; Gansevoort, R.; Martino, G.; Raso, F. M.; Nistor, I.; Ortiz, A.; Paolisso, G.; Rastenyte, D.; Stefan, G.; Tedeschi, G.; Massy, Z. A.; Bikbov, B.; Endlich, K. H.; Godefroy, O.; Chillon, J. -M.; Kossioni, A.; Kurganaite, J.; Perico, N.; Remuzzi, G.; Grodzicki, T.; Trepiccione, F.; Zoccali, C.; Arici, M.; Blankestijn, P.; Eckardt, K. -U.; Fliser, D.; Jimenez, E. G.; Konig, M.; Rychlik, I.; Deleidi, M.; Reusz, G.. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 37:(2022), pp. 23-32. [10.1093/ndt/gfab262]

Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment

Martino G.;
2022-01-01

Abstract

Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.
2022
chronic kidney disease
clinical assessment
cognitive impairment
cognitive screening test
comprehensive battery
File in questo prodotto:
File Dimensione Formato  
gfab262.pdf

accesso aperto

Tipologia: Submitted manuscript (manoscritto inviato all’editore)
Licenza: Creative commons
Dimensione 1.48 MB
Formato Adobe PDF
1.48 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/145576
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 21
social impact